Discovery of Chromone Derivatives as Selective BLT1 Inhibitors for Alleviating Acute Lung Injury and Sepsis

(20 mg/kg, p.o.) conferred significant protection against acute lung injury and sepsis, with favorable oral bioavailability (F% = 85.3) and a good safety profile. This work provides a structural basis for developing novel selective BLT1 inhibitors and offers new insights for anti-inflammatory drug discovery.